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           Persistent infection with hepatitis B virus (HBV) 
remains a major global health threat, currently 
aff  ecting over 350 million individuals world-
wide and causing more than 1 million deaths 
annually. Immune clearance is thought to be 
mediated primarily through a strong virus-spe-
cifi  c CD8 T cell response (  1  ); marked quantita-
tive and qualitative defects in this response have 
been described in patients with chronic HBV 
infection (CHB) (  2  –  4  ). Patients with uncon-
trolled infection are distinguished from healthy 
HBV carriers by the presence of a large lym-
phocytic infi  ltrate in their livers, containing a 
high proportion of non  –  antigen-specifi  c CD8 
T cells (  3, 5  ). Little is known about the charac-
teristics of this generalized CD8 T cell popula-
tion and its potential contribution to the failure 
of viral control and liver immunopathogenesis. 
In this study, we defi  ne the functional profi  le of 
non  –  HBV-specifi  c CD8 T cells in patients with 
CHB, and investigate aberrant expression of the 
proximal TCR-associated signaling molecules 
CD3     and CD28 as putative mechanisms con-
tributing to the defects seen. 
  In other diseases of chronic infl  ammation 
and high-load antigenic persistence analogous to 
the situation in CHB, selective defects in global 
CD8 function have been associated with down-
regulation of CD3       ±   CD28. These include 
autoimmune disorders (  6, 7  ), malignancy (  8  ), and 
chronic viral (  9, 10  ) and bacterial (  11  ) infections. 
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  The infl  amed liver in chronic hepatitis B virus (HBV) infection (CHB) is characterized by a 
large infl  ux of non  –  virus-specifi  c CD8 T cells. Little is known about the functional capacity 
of these lymphocytes, which could provide insights into mechanisms of failure of viral 
control and liver damage in this setting. We compared the effector function of total circu-
lating and intrahepatic CD8 T cells in CHB patients and healthy donors. We demonstrated 
that CD8 T cells from CHB patients, regardless of their antigen specifi  city, were impaired in 
their ability to produce interleukin-2 and proliferate upon TCR-dependent stimulation. In 
contrast, these CD8 T cells had preserved production of the proinfl  ammatory cytokines 
interferon-     and tumor necrosis factor-    . This aberrant functional profi  le was partially 
attributable to down-regulation of the proximal T cell receptor signaling molecule CD3    , 
and could be corrected in vitro by transfection of CD3     or replenishment of the amino acid 
arginine required for its expression. We provide evidence for depletion of arginine in the 
infl  amed hepatic microenvironment as a potential mechanism for these defects in global 
CD8 T cell signaling and function. These data imply that polarized CD8 T cells within the 
HBV-infected liver may impede proliferative antiviral effector function, while contributing 
to the proinfl  ammatory cytokine environment. 
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tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
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plicates a role for arginine deprivation triggering CD3     down-
regulation and impairing T cell proliferation. 
    RESULTS   
  CD8 T cells from CHB patients display reduced IL-2 
and proliferative capacity upon stimulation through the TCR 
  To investigate the functional properties of the global CD8 T 
cell population in CHB, we performed a cross-sectional study 
comparing patients with diff  erent HBV disease profi  les and 
healthy controls (  Table I  ).   PBMCs were isolated and stimulated 
with either TCR-dependent mitogens (anti-CD3/anti-CD28) 
or TCR-bypassing mitogens (PMA/ionomycin); eff  ector func-
tion was measured by intracellular cytokine or CFSE staining. 
Representative examples of CD8 eff  ector functions in a con-
trol, low-level, and high-level CHB patient are shown in 
  Fig. 1 a   (top to bottom: IL-2, IFN-    , TNF-    , and CD107).   
Cumulative data for 15 healthy controls, 16 CHB patients 
with viral load   <  10  6   IU/ml, and 13 CHB patients with viral 
load   >  1   ×   10  6   IU/ml are shown in   Fig. 1 b  . Upon a TCR-
dependent stimulus (anti-CD3 and -CD28), there was a sig-
nifi  cant impairment in CD8 T cell IL-2 production in CHB, 
with a mean fourfold decrease in patients with high viral load 
compared with the controls (P   <   0.001, Mann-Whitney test). 
There was a trend to progressive impairment with high viral 
load (  >  10  6   IU/ml) and raised alanine transaminase (alanine 
aminotransferase [ALT]   >  50 IU/liter, surrogate marker for 
liver infl  ammation;   Fig. 1 b  ). 
  In contrast, CD8 production of IFN-     was maintained in 
patients with high HBV load, liver infl  ammation, and expres-
sion of eAg compared with healthy carriers or healthy donors 
(  Fig. 1, a and b  ). Similarly, TNF-     production and cytolytic 
potential (measured by surface expression of CD107) of global 
CD8 T cells were maintained in CHB, and tended to be 
higher in patients with active disease (  Fig. 1, a and b  ). Using 
PMA and ionomycin as a TCR bypassing signal, no diff  er-
ences in CD8 T cell eff  ector function could be detected be-
tween CHB patients and controls (shown for IFN-     and IL-2; 
  Fig. 1 c  ). This indicated that the functional biases noted could 
not be attributed to the increase in CD27       CD45RA  +   CD8 in 
CHB (unpublished data) because these   “  end-stage  ”   eff  ectors 
have impaired IL-2 production upon PMA/ionomycin stimu-
lation (  23  ). Instead, it pointed to the skewed CD8 eff  ector 
function resulting from aberrations within the TCR-associated 
The CD3     chain is a proximal TCR-associated signaling 
molecule comprised of a disulphide-linked homodimer (  12  ). 
Upon TCR ligation, SRC family kinases phosphorylate 
the three ITAM residues on the intracytoplasmic domain of 
CD3    , and these then serve as docking sites for adaptor pro-
teins such as ZAP-70, which potentiate further downstream 
signaling events. CD3     is structurally and evolutionarily unique 
from other CD3 components and plays a rate-limiting role in 
TCR  –  CD3 complex assembly and effi   cient signal amplifi  ca-
tion (  13, 14  ). Along with CD3    , down-regulation of CD28, 
a proximal costimulatory molecule required for effi   cient sig-
naling has also been described in viral infections (  15  ) and as-
sociated with T cell anergy. 
  Selective defects in virus-specifi  c CD8 T cell function 
have been described in several chronic viral infections and 
observed to be progressively lost in a predictable hierarchy 
according to the duration and strength of antigenic stimula-
tion and availability of CD4 help (  16, 17  ). Loss of CD8-
derived IL-2 is an early defect that has recently been found 
to result in poor viral control and disease outcome in HIV 
infection (  10, 18  ). Functional defects aff  ecting nonantigen-
specifi  c CD8 would need to invoke factors other than ex-
cessive antigenic drive through MHC/peptide interactions. 
Bystander activation and eff  ects of the large quantities of 
circulating HBV antigens are possible candidates. In addi-
tion, the liver microenvironment, where the nonantigen-
specifi  c CD8 T cells accumulate in HBV infection, has long 
been recognized to be immunotolerant. In active HBV in-
fection, intrahepatic T cells would be exposed to a high level 
of production of HBV antigens and recurrent hepatic in-
fl  ammation. Putative factors aff  ecting non  –  antigen-specifi  c 
T cells include high levels of proinflammatory cytokines, 
hepatocyte expression of tolerizing ligands (  19  ), depletion 
of essential nutrients (  20  ), or accumulation of toxic metab-
olites (  21, 22  ). 
  In patients with CHB, we found a skewing of eff  ector 
function in all CD8 T cells, regardless of their specifi  city. 
Compared with healthy donors, CHB patients had circulating 
and intrahepatic CD8 T cells with poor IL-2 production and 
proliferative potential. Our fi  ndings point to a dual patho-
genic role for nonantigen-specifi  c CD8 T cells within the 
liver, contributing to both liver infl  ammation and poor viral 
control. Investigation of the underlying signaling defects im-
    Table I.        Clinical characteristics of patients and controls 
  Overall CHB Low viral load High viral load Healthy donor
  n 58 35 23 28
Median age (range) 35 (23  –  69) 35 (23  –  69) 36 (23  –63  ) 28 (22  –44  )
Sex (M:F ratio) % male (41:17) 70% (25:10) 71% (16:7) 70% (14:14) 50%
Median serum HBVDNA (IU/ml; range) 250,000 
   (BLQ  –  340   ×   10  6  )
1,400 
   (BLQ  –  945700)
78   ×   10  6      (1.1   ×   10  6    –  340   ×   10  6  )-
Median ALT (IU/liter; range) 50 (21  –  498) 36 (21  –  498) 73 (24  –  363) -
HBeAg status (% positive) 11% 10% 87% -
BLQ, DNA positive but below limit of quantifi  cation, i.e.,   <  50 IU/ml.JEM VOL. 205, September 1, 2008 
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of IL-2 production would be expected to limit T cell clonal 
expansion potential, particularly within the liver, where CD4 
help is restricted (  24  ). To test this, we measured the prolifera-
tive capacity of CD8 T cells upon mitogenic stimulation by 
CFSE dilution. Consistent with their impaired IL-2 produc-
tion and/or a direct block of cell cycle progression, fewer 
CD8 T cells from patients with CHB divided, and those that 
did divide underwent fewer divisions than CD8 T cells from 
signaling machinery. This was supported by the fact that cyto-
kine skewing was maintained upon substituting anti-CD3/
CD28 stimulation with plate-bound anti-CD3 alone or anti-
CD3 in combination with irradiated APC. 
  CD8 T cells with this altered IFN-    /IL-2 ratio have re-
cently been noted in other chronic viral infections, such as 
HIV and LCMV, and they were found to correlate with poor 
viral control and disease progression (  17, 18  ). This impairment 
    Figure 1.         Selective impairment in IL-2 production and proliferation, but elevated IFN-    , TNF-    , and cytolysis, in CD8 T cells from patients 
with high viral load.   PBMCs were stimulated with mitogens OKT3 (anti-CD3; 1   μ  g/ml) and anti-CD28 mAb (5   μ  g/ml), and cytokine production in CD8 T 
cells was determined by intracellular cytokine staining. (a) Representative dot plots show IL-2, IFN-   ,  TNF-   , CD107, and CFSE staining by CD8 T cells in a 
healthy donor, patient with low viral load (  <  10  6   IU/ml HBVDNA), and a patient with high viral load (  >  10  6   IU/ml HBVDNA). (bottom) Percentage of CFSE 
low CD8 T cells in a control (dark gray histogram), low-level carrier (solid black line), and high-level carrier (light gray histogram). The y axis shows the 
percentage of maximum counts to standardize overlaid histogram heights. (b) Subjects were categorized into groups determined by their viral load/
HBeAg status or level of liver infl  ammation (ALT as a surrogate marker of liver infl  ammation) and mean (  ±   SEM) production of cytokines IL-2, IFN-   , 
TNF-    , the cytolytic marker CD107, and divisions as determined by CFSE are shown for each group after anti-CD3/anti-CD28 stimulation. Background pro-
duction of cytokines was determined in the unstimulated control, and subtracted from the fi  nal readings (*, P   <   0.05; **, P   <   0.01; ***, P   <   0.001, all 
signifi  cance testing by the Mann-Whitney test). (c) Levels of intracellular IL-2 and IFN-     in the different donors after TCR-independent stimulation 
with PMA/ionomycin.     2114 CD8 SKEWING IN HBV INFECTION   | Das et al. 
with peptides representing immunodominant HLA-A2  –  re-
stricted viral epitopes from CMV, EBV, and infl  uenza A, in 
addition to HBV (  Fig. 2 a  ).   Virus-specifi  c CD8 from healthy 
donors produced predominantly IFN-    , but had a clear pop-
ulation of dual IFN-    /IL-2  –  responding cells, whereas those 
from CHB patients only produced IFN-     (  Fig. 2 a  ). The 
percentage of IFN-      –  positive to dual IFN-    /IL-2  –  positive 
peptide-specifi  c CD8 T cells was plotted as a ratio after sub-
traction of background readings from controls without pep-
tide. As shown in   Fig. 2 b  , regardless of the virus specifi  city, 
there was a signifi  cantly higher IFN-    /IL-2 ratio in patients 
with active HBV infection compared with healthy donors 
(P   <   0.01). Because CMV infection has also been reported to 
skew the repertoire of T cell responses (  27  ), and was there-
fore a potential confounding factor, we also compared exclu-
sively CMV-specifi  c responses in a subset of CHB patients 
and controls who were known to be CMV seropositive. The 
proportion of CD8 able to produce IL-2 in response to the 
immunodominant HLA-A2  –  restricted NLV epitope from 
pp65 showed a stepwise reduction from healthy donors to 
low- and high-level CHB patients (  Fig. 2 c  ). These data fur-
ther confi  rm that functional impairment is present in the gen-
eralized T cell population in patients with CHB, regardless of 
antigen specifi  city. 
controls (  Fig. 1, a and b  , bottom). The proportion of CD8 T 
cells able to undergo at least one division was signifi  cantly re-
duced in CHB patients with high viral load and expression of 
eAg, and showed a negative correlation with liver infl  amma-
tion within the patient group (r  2   = 0.6; P   <   0.04; unpublished 
data). Impaired CD8 division was seen upon stimulation of 
whole PBMCs, indicating that the available CD4 help could 
not compensate for the CD8 defect in these patients. Com-
patible with this, reduced IL-2 production by CD4 T cells 
was also noted in patients with HBV infection compared with 
healthy controls (unpublished data). 
  Skewed IFN-    /IL-2 ratio in CD8 T cells from CHB patients 
regardless of specifi  city 
  HBV-specifi  c CD8 T cells are markedly depleted in patients 
with CHB (  3  ), such that circulating responses are barely de-
tectable, even when overlapping peptides covering the whole 
genome are applied (  25, 26  ). Based on this fi  nding, it is log-
ical to assume that the majority of the CD8 T cells we are 
studying in the periphery of these patients are non-HBV 
  specifi  c. To confi  rm that the qualitative dysfunction we ob-
served was not restricted to the HBV-specifi  c CD8 T cells 
but also extended to other virus specifi  cities, PBMCs from 
HLA-A2  –  positive donors were stimulated directly ex vivo 
    Figure 2.         Determination of IL-2 and IFN-     production by CD8 T cells after     stimulation with HLA-A2  –  restricted viral peptides.  (a)  Represen-
tative fl  ow cytometric dot plots to show distribution of IFN-     and IL-2  –  positive responder cells after ex vivo stimulation with peptides (for IFN-A, CMV, 
HBV envelope pool) in a healthy donor and in a high-level carrier. All ex vivo responses were in the range of 0.1  –  4% after subtraction of background 
readings. A response was determined as any reading   >   mean + 2SD of background. (b) Cumulative data to show mean IFN-    /IL-2 ratio after stimulation 
with peptides (NLV,      ; EBV,      ; FLU,      ; HBV c18-27/ env pool,      ) for controls, and patients with low (  <  10  6   IU/ml) and high (  >  10  6   IU/ml) viral load. 
(c) Histogram to show proportion of double-positive (IFN-    + IL-2 + /IFN-   +  ) CD8 T cells in controls and patients after stimulation with the NLV peptide of 
CMV ex vivo. Mean and SEM are shown.     JEM VOL. 205, September 1, 2008 
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and six controls without HBV infection. Control liver sam-
ples included liver tissue with normal architecture and unin-
fl  amed histology taken distal to a metastasis and tissue from 
patients with other infl   ammatory liver diseases (  Table II  ).   
  After isolation, intrahepatic lymphocytes were stimulated di-
rectly ex vivo with TCR-dependent mitogens, and IFN-     
and IL-2 production was determined in gated CD8 T cells 
(  Fig. 3 a  ).   In non  –  HBV-infected patients, the following 
three populations of responder cells could be seen: IFN-     
  Intrahepatic CD8 T cells produce less IL-2 in patients 
with CHB than in controls 
  CD8 T cells are enriched in the liver compared with the pe-
riphery (  24  ), with CD8 T cells constituting 60  –  90% of intra-
hepatic T cells. To better understand what role this population 
may play in HBV-associated infl  ammation and/or viral con-
trol, intrahepatic CD8 T cells were isolated and studied. Liver 
tissue was obtained from routine diagnostic biopsies or re-
sected tissue from six patients with HBV-related liver disease 
    Table II.        Clinical characteristics of patients and controls for liver samples 
Subject Pathology ALT 
  (IU/liter)
HBeAg Sex Age
H1    a    CHB mild fi  brosis 45 NEG Male 31
H2    a    CHB mild fi  brosis 100 POS Male 23
H3    a    CHB moderate fi  brosis 246 POS Male 42
H4     a      ,      b   CHB  cirrhosis 498 NEG Male 34
H5    a    CHB no fi  brosis  48 NEG Male 43
H6    a    CHB mild fi  brosis 63 NEG Male 43
H7    b   CHB    d   40 - Male 60
H8    b   CHB    d   56 - Male 66
H9    b   CHB    d   110 - Male 56
H10    b   CHB    d   79 - Male 44
H11    b   CHB    d   45 - Female 48
H12    c   CHB  cirrhosis 31 - Male 54
H13    c   CHB  fi  brosis 67 NEG Male 49
H14    c   CHB  cirrhosis 54 NEG Male 53
H15    c   CHB  cirrhosis 47 NEG Male 50
H16    c    CHB + hepatocellular carcinoma 19 NEG Male 61
C1    a      ,      b   Nonprimary 
   liver  carcinoma    e   
140 N/A Female 34
C2    a   Nonprimary 
   liver  carcinoma    e   
26 N/A Female 56
C3    a      ,      b   Cholangiocarcinoma 41 N/A Female 34
C4    a   Nonprimary 
   liver  carcinoma    e   
34 N/A Male 60
C5  a,b Nonprimary 
   liver  carcinoma    e   
17 N/A Female 67
C6    a   Nonprimary 
   liver  carcinoma    e   
209 N/A Male 66
C7    b    Hepatitis C virus infection 54 N/A Female 41
C8    b   Nonprimary 
   liver  carcinoma    e   
30 N/A Female 60
C9    b   Nonprimary 
   liver  carcinoma    e   
30 N/A Male 54
C10    b   Nonalcoholic  steatohepatitis 108 N/A Female 32
C11    c    Healthy transplant donor - N/A Male 56
C12    c   Alcoholic  cirrhosis 19 N/A Male 63
C13    c    Primary sclerosing cholangitis 138 N/A Female 29
C14    c    Primary sclerosing cholangitis 69 N/A Female 60
C15    c    Primary sclerosing cholangitis - - Female -
  a  Used for functional ICS.
  b  Used for CD3     staining.
  c  Used for arginase activity.
  d  CHB, histology unavailable.
  e  Resection specimens adjacent to nonprimary liver carcinoma; all tissue was of normal architecture.2116 CD8 SKEWING IN HBV INFECTION   | Das et al. 
single-positive, IFN-    /IL-2 double-positive, and IL-2 single-
positive. In each of the six CHB-infected donors, however, 
intrahepatic CD8 T cells almost exclusively produced IFN-    , 
resulting in a signifi   cantly raised mean IFN-    /IL-2 ratio 
compared with the non  –  HBV-infected group (P   <   0.01;   Fig. 
3 b  ). These data revealed a dysfunction in global intrahepatic 
CD8 T cell IL-2 production in CHB. 
  CD8 T cells from patients with CHB have selective down-
regulation of the CD3     chain, which is more marked 
in the intrahepatic compartment 
  The identifi  cation of a selective defect in IL-2 and prolifera-
tion after a TCR-dependent stimulus, but not upon a TCR-
bypassing stimulus, pointed to dysfunction within the TCR 
signaling machinery. In other chronic infectious diseases such 
as HIV (  10  ), impairment in IL-2 production has been par-
tially attributed to down-regulation of the CD3     chain, a 
    Figure 3.         Intrahepatic CD8 T cells from patients with CHB are 
biased toward IFN-     over IL-2 production.   (a) Intrahepatic CD8 
T cells were isolated from liver biopsies, and cytokine production was 
determined by intracellular staining after anti-CD3/anti-CD28 stimulation. 
Representative dot plots show IL-2 and IFN-     production by CD8 T cells 
for a typical patient with chronic HBV and a patient with nonviral liver 
pathology. (b) After mitogenic stimulation, the ratio of IFN-   /IL-2  pro-
duction by intrahepatic CD8 T cells was determined for six patients 
with CHB and six patients without CHB. Ratios are plotted in the histo-
gram shown.          Figure 4.         CD3     is down-regulated in both peripheral and intrahe-
patic CD8 from patients with chronic HBV.   PBMCs or intrahepatic 
lymphocytes isolated from biopsy tissue were surface stained for CD3    
and CD8, fi  xed, permeabilized, and stained for intracellular CD3     or its 
isotype. A tight lymphocyte gate and secondary gate over CD3    + CD8  cells 
has been applied. A marker was applied at the edge of the isotype control 
(solid black line) and the proportion of CD8 to the right of this line repre-
sented the CD3    +   fraction. (a) Representative fl  ow cytometric histogram 
illustrating CD3     expression (as a percentage and as mean fl  uorescence 
intensity [MFI]) for a chronic HBV-infected patient with high viral load 
( > 10 6   IU/ml; dashed line) and a healthy control (gray). (b) CD3     levels, 
shown as both MFI and percentage of CD3    +   in the total CD8 are shown 
against viral load (top), and percentage values are further broken down 
by HBeAg status and ALT (bottom). (c) Histogram to illustrate differential 
expression of CD3     by peripheral (dark gray) and intrahepatic (light gray) 
CD8 from a CHB donor (dotted line, isotype). (d) The difference in CD3    
expression between intrahepatic and peripheral CD8 is plotted for each 
patient with HBV/non-HBV  –  related liver disease.     JEM VOL. 205, September 1, 2008 
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proximal TCR-associated signaling molecule (  12  ). This mol-
ecule can be down-regulated independently of other CD3 
signaling molecules, which maintain their expression on the 
cell surface. T cells with low (  10, 15, 28  ) or absent (  29  ) CD3     
maintain IFN-    , but not IL-2 production, and become refrac-
tory to TCR-induced proliferation. To determine whether 
CD3     down-regulation could be a factor contributing to the 
functional defects seen, we compared CD3     expression be-
tween controls (  n   = 16) and patients with low (  n   = 20) and 
high HBV load (  n   = 12). CD3     expression was determined 
by intracellular staining after gating on CD3    , so that de-
tected diff  erences in the expression of CD3     would not be 
caused by down-regulation of the entire CD3 complex, but to 
isolated down-regulation of the CD3     homodimer (anti-CD3     
binds an extracellular domain on the CD3     chain and does 
not interfere with binding of anti-CD3     to its intracellular 
determinant). Representative CD3     expression after gating 
on CD3      +  CD8 cells is shown for a CHB patient and healthy 
donor in   Fig. 4 a  .   
  To determine whether CD3     down-regulation corre-
lated with disease status, patients were categorized by their 
viral load (  <  10  6   or   >  10  6   IU/ml), HBeAg status, or ALT level 
(raised   >  50 IU/liter). Patients were classed as ALT high if 
their ALT was raised at the time of sampling or had been 
raised in the previous 6 mo to take account of patients with 
cyclical fl  ares of liver infl  ammation. CD3     expression in CD8 
T cells correlated inversely with each of the three parameters 
(P   <   0.0001;   Fig. 4 b  ). Patients with the most active HBV in-
fection had the lowest CD3     expression in their CD8 T cells, 
with a mean reduction of 40% compared with controls. Ex-
pression of CD3     was also reduced in CD4 T cells from these 
patients, but to a lesser degree than the CD8 T cells (unpub-
lished data), as noted previously in HIV infection (  9  ). 
  CD3     down-regulation has been attributed to exposure to 
sustained infl  ammatory cytokines and antigenic stimulation; 
therefore, we hypothesized that it would be more pronounced 
in the intrahepatic compartment, which is the site of HBV re-
plication and associated pathology. Intrahepatic lymphocytes 
were therefore isolated from six CHB patients and seven non  –
  HBV-infected patients undergoing diagnostic liver biopsies. 
For each patient, CD3     expression in intrahepatic and periph-
eral T cells was compared (  Fig. 4 c  ). CD3     expression was 
lower in intrahepatic than peripheral CD8 T cells for all CHB 
patients, with a mean of 24% fewer CD3      +   cells in the liver 
compared with the periphery (  Fig. 4 d  ). However, in the seven 
non  –  HBV-infected patients, we found signifi  cantly less diff  er-
ence in CD3     expression between peripheral and intrahepatic 
T cells (  Fig. 4 d  ). These data suggest that CD3     down-regulation 
may be potentiated by the combination of chronic viral-driven 
infl  ammation and other factors that are more pronounced in 
the CHB liver microenvironment. 
  CD28 is also down-regulated in CHB patients 
  Like CD3    , down-regulation of CD28 has been described 
in chronic viral infections such as HIV and CMV and has 
been associated with T cell anergy (  15  ). CD8 T cells that are 
CD28        in CHB are more likely to have down-regulated 
CD3     than their CD28  +   counterparts, but these two proximal 
signaling molecules are not always down-regulated together 
(  Fig. 5 a  ).   To investigate whether CD28 down-regulation 
could be playing a role in chronic HBV, we compared sur-
face CD28 staining of CD8 T cells from patients and con-
trols. The percentage of CD8 T cells expressing CD28 was 
reduced in CHB compared with healthy controls (  Fig. 5 b  ). 
    Figure 5.         CD28 is down-regulated in CD8 T cells from patients 
with high viral load.   (a) Representative dot plot to show the co-
expression of CD28 and CD3     in CD8 T cells in a patient with high viral 
load. (b) Flow cytometric histogram to show the proportion of CD8 T cells 
that are CD28  +   in a patient with high viral load (gray) and a healthy donor 
(dashed line). (c) Cumulative data for CD28 expression is shown against 
viral load, HBeAg status, and ALT level.     
    Figure 6.         Reconstitution of CD3     and CD28 levels with a chimeric 
receptor reverses the IL-2 defect.   (a) Histogram shows transfection 
effi  ciency in a representative patient after transfection of a chimeric re-
ceptor with an extracellular CD33-binding domain and intracellular CD3    
and CD28 domains. (b) After antigen-specifi  c stimulation through the 
chimeric receptor, TCR (anti-CD3/anti-CD28), or both together, IL-2 pro-
duction was determined by ELISA. Mean and SEM of IL-2 production is 
shown for three individuals after the varying stimuli.     2118 CD8 SKEWING IN HBV INFECTION   | Das et al. 
CD28 was signifi  cantly down-regulated in CD8 T cells from 
patients with high viral load, eAg expression, and liver in-
fl  ammation (  Fig. 5 c  ). The expression of CD28 is known to 
be aff  ected by CMV status and age (  27  ); data were therefore 
reanalyzed, including only age-matched CMV-seropositive 
individuals in the control and CHB groups; CD28 was still 
reduced in CHB patients with high viral load compared with 
low-level carriers or controls (unpublished data). 
  Transfection of CD3    /CD28 corrects the IL-2 defect in CD8 
T cells from CHB patients 
  Our data suggested an association between down-regulated 
CD3    , and impaired IL-2 production, with a possible further 
contribution from CD28 down-modulation in patients with 
the most active disease. To confi  rm this functional association, 
we sought to specifi  cally reconstitute levels of these two sig-
naling molecules in CD8 T cells from CHB patients and assess 
the impact on their functional skewing. Freshly isolated, un-
stimulated CD3    CD28  lo   CD8 T cells from patients with CHB 
were transfected by electroporation with plasmid DNA en-
coding a chimeric receptor with intracellular CD3     and CD28 
domains, as previously described (  30, 31  ). These chimeric re-
ceptors had the human antibody P67 specifi  city for CD33 an-
tigen; detection using fl  uorescent, soluble CD33Ag indicated 
a transfection effi   ciency of at least 60% (  Fig. 6 a  ).   After an 
overnight rest, transfected PBMCs were then stimulated with 
anti-CD3 and -CD28, which activated the cells through the 
TCR, with or without the addition of CD33Ag, which bound 
to the extracellular P67 domain of the chimeric receptor. The 
same experiments were repeated on untransfected cells that 
had also been passed through the AMAXA transfection proto-
col with PBS in place of DNA. When PBMCs or negatively 
selected CD8 T cells were stimulated through the TCR or 
through CD33 alone, low levels of IL-2 production were de-
tectable by ELISA. Addition of both stimuli together substan-
tially increased IL-2 production (  Fig. 6b  ). Production of IL-2 
by the dual stimulus exceeded the combined additive eff  ect of 
the TCR-dependent or transfection-specifi  c stimuli separately. 
This suggests that the newly introduced CD3     and CD28 may 
not only be activated after the CD33Ag stimulus, but may also 
be recruited to TCR signaling after CD3/CD28 stimuli. Un-
transfected cells showed no increase in IL-2 production upon 
addition of CD33Ag stimulation. We were unable to exclude 
the possibility that some of the functional enhancement de-
rived from increased signaling of   “  normal  ”   cells rather than 
recovery of the specifi  c population of cells defi  cient in CD3    /
CD28. However, these data at least directly confi  rm the link 
between overall levels of CD3    /CD28 and capacity for IL-2 
production in CD8 T cells from CHB patients. 
    Figure 7.         Replenishment of arginine restores CD8 expression of 
CD3    , accompanied by a recovery in IL-2 production and prolifera-
tion.   (a) Histogram illustrates effect of overnight culture in medium on 
CD3     levels (black histogram) compared with when measured directly 
ex vivo (gray histogram). Isotype control is shown as the dotted line. IL-2 
production was determined in parallel before and after culture and repre-
sentative plots are shown. (b) Cumulative data to show change in CD28 
(P = nonsignifi  cant) and CD3     expression (P   <   0.0001) after in vitro culture, 
compared with ex vivo culture, in fi  ve and nine patients, respectively. 
(c) CD3     expression in CD8 T cells was determined directly ex vivo, and 
then again after overnight culture in medium with or without   L- arginine 
(0.2 g/liter). (d) To investigate whether the presence of   L-  arginine affects CD8 
T cell proliferation, PBMCs were preincubated with medium with or without   
L-  arginine for 24 h, stained with CFSE, and resuspended in their respective 
mediums in the presence of a CD3    -dependent stimulus for 6 d. A gate 
has been applied on CD8 T cells. (e) To determine the effect of   L- arginine 
on proliferation of HBV-specifi  c CD8  +   T cells, PBMCs from HLA-A2  +   pa-
tients who had resolved HBV infection were stimulated with core 18  –  27 
peptide for 7 d and detected with an HLA-A2/c18-27  –  specifi  c tetramer. 
Representative dot plots depict the HBV-specifi  c CD8  +   population  ex-
panded at 1 wk, along with the number of divisions these populations 
have undergone, determined by CFSE dilution, in the presence (top) or 
absence (bottom) of   L-  arginine. (f) Cumulative data illustrate the effect of 
depleting   L-  arginine on the percentage of tetramer-positive populations 
dividing by 1 wk in 5 patients (P   <   0.01). (g) HLA-A2/core18-27 tetramer-
positive CD8 were compared after 7-d peptide stimulation of PBMCs in-
cubated in a range of   L-  arginine concentrations (0   μ  M, 5   μ  M, 25   μ  M, 
50   μ M,  150   μ M,  and  1  mM).   
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  We then investigated the potential impact of this argi-
nine-dependent functional defect on the HBV-specifi  c CD8 
T cell response, which is essential to control viraemia (  1  ). HBV-
specifi  c responses were effi   ciently expanded from the blood 
of patients who had controlled HBV infection (as refl  ected by 
the percentage of CD8 staining with a HLA-A2/core 18  –  27-
specifi  c tetramer), and by 1 wk in culture the majority had 
divided as assessed by CFSE staining (  Fig. 7 e  , top). When these 
responses were cultured in an arginine-depleted environment, 
they resembled CD8 from patients with high HBV load 
(  Fig. 1  ) (  3  ), showing a marked reduction in clonal expansion 
(  Fig. 7 e  , bottom). Only a minority of HBV-specifi  c CD8 
had divided by 1 wk in arginine-depleted medium, and in 
every case there was inhibition of proliferation compared with 
responses in the presence of arginine (  Fig. 7 f  ; P   <   0.01). This 
proliferative impairment resulted in reduced in vitro expansion 
of HBV-specifi  c CD8 (  Fig. 7 e  ). When arginine-free medium 
was supplemented with increasing concentrations of arginine, 
a dose-dependent impairment in expansion of HBV-specifi  c 
CD8 was observed (  Fig. 7 g  ). 
  In vivo levels of arginine and arginase correlate with HBV 
disease activity 
  To investigate whether T cells would be exposed to an envi-
ronment depleted of arginine in patients with CHB, we ini-
tially measured   l  -arginine levels in their serum. We found 
signifi  cantly reduced levels of arginine in the circulation of 
CHB patients with marked liver infl  ammation (ALT   >   100 
  Functional reconstitution of CD3     in CD8 T cells from CHB 
patients is partially dependent on   L  -arginine 
  We observed that after overnight culture of CD8 T cells from 
CHB patients in complete medium, levels of intracellular 
CD3     were reconstituted to levels found in healthy controls 
(  Fig. 7 a  , histogram).   This CD3     reconstitution was accom-
panied by a recovery in IL-2 production from the reduced 
levels produced by CD8 directly ex vivo to normal levels 
(  Fig. 7 a  , FACS plots). Recovery of CD3     expression was seen 
consistently after overnight culture for all samples from CHB 
patients, whereas CD28 levels in these patients did not show 
a concurrent increase over the same period (  Fig. 7 b  ). The fact 
that substantial functional reconstitution accompanied CD3     
up-regulation in cells that had not altered their CD28 levels 
indicated that CD3     down-regulation may be the more rele-
vant defect in this situation. 
  These fi  ndings suggested that removal or replenishment 
of a factor in vitro enabled CD3     to be reexpressed at physio-
logical levels in CD8 T cells from patients with CHB. One 
candidate for such an eff  ect was   l  -arginine because depletion 
of this conditionally essential amino acid has been associated 
with CD3     down-regulation in human T cells (  32  ). To investi-
gate whether   l  -arginine levels modulate CD3     expression in 
T cells of patients with CHB, PBMCs were cultured overnight 
in medium with or without   l  -arginine and CD3     expression 
was subsequently determined. When medium depleted of 
  l  -arginine was used, up-regulation of CD3     was attenuated 
compared with the reconstitution that could be achieved 
upon the addition of   l  -arginine at the concentration found in 
the usual complete medium (  Fig. 7 c  ). To investigate whether 
functional diff  erences could be attributed to these altered lev-
els of CD3     reconstitution, proliferative capacity of CD8 T 
cells was determined after 6 d of culture with a TCR-depen-
dent stimulus in medium with or without   l  -arginine. PBMCs 
were rested in their respective mediums for 24 h before stim-
ulation, to allow suffi   cient time for CD3     levels to be infl  u-
enced by the extracellular   l  -arginine microenvironment at 
the point of triggering of proliferation. We observed that the 
proliferation of CD8 T cells taken from CHB patients and 
cultured in   l  -arginine  –  free medium was lower than that for 
CD8 T cells cultured in medium with   l  -arginine (  Fig. 7 d  ). 
In the absence of arginine supplementation, CD8 T cells from 
CHB patients had a profound block in proliferation, and a 
partial block to proliferation persisted in serum supplemented 
with arginine in the physiological concentration range (unpub-
lished data). These data suggest that the CD3     down-modu-
lation and IL-2/proliferative defi  ciency observed directly ex 
vivo in CD8 T cells from patients with CHB may be partially 
attributable to deprivation of   l  -arginine. In addition to loss 
of proliferative function caused by CD3     down-regulation, 
  l  -arginine deprivation has also been directly linked to growth 
arrest at the G0-G1 phase of the cell cycle (  33  ), which is com-
patible with the striking loss of CD8 proliferation we ob-
served. Once these cells were removed from factors present 
in the HBV-infected patient, they were susceptible to func-
tional reconstitution. 
    Figure 8.         Depletion of serum   L-  arginine is associated with ele-
vated serum and liver arginase activity during periods of HBV dis-
ease activity in patients with CHB.   (a)  Serum   L-  arginine levels were 
compared in healthy donors (  n   = 21), patients with low-to-moderate liver 
infl  ammation (ALT   <   100 IU/liter;   n   = 13), and patients with high liver 
infl  ammation (ALT   >   100 IU/liter;   n   = 11; control vs. high ALT P   <   0.01; 
low ALT vs. high ALT P   <   0.05). (b) Graphs depict longitudinal fl  uctuations 
in serum arginase activity (dashed line, IU/liter) in association with viral 
load (solid gray line, HBV DNA, IU/ml) and ALT (shaded histogram, IU/liter) 
for two patients with fl  ares of CHB. (c) The arginase activity of liver 
  homogenates is shown for fi  ve individuals with CHB and fi  ve individuals 
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we elucidated a mechanism that may contribute to the failure 
of virus-specifi  c CD8 to survive and proliferate suffi   ciently to 
control HBV replication. 
  The study of HBV-specifi  c CD8 has been restricted by 
the diffi   culty in detecting these cells in patients failing to con-
trol HBV infection. We have previously noted that the scanty 
populations detectable in patients with CHB have an im-
paired capacity for clonal expansion (  3, 26, 38  ) and an en-
hanced propensity to Bim-mediated apoptosis (  39  ). In this 
study, we identify a mechanism that could contribute to both 
of these defects, resulting in an impairment of HBV-specifi  c 
CD8 proliferation and a generalized intrahepatic T cell defi  -
ciency in IL-2 production in CHB. CD8 T cells have been 
shown to depend on autologous IL-2 production to drive 
their replication in settings of impaired CD4 help (  18  ), such 
as the CD4-depleted liver in CHB (  24, 40  ). A local depletion 
in IL-2 could also contribute to the propensity of HBV-spe-
cifi  c CD8 to undergo apoptosis through the IL-2-dependent 
Bcl-2 pathway (  39  ). The impairment in IL-2 production 
manifested by nonantigen-specifi  c CD8 T cells could there-
fore impact upon the ability of the HBV-specifi  c populations 
to both expand   and   survive. A generalized defect in the abil-
ity to mount effi   cient T cell responses in patients with CHB 
is supported by the long-standing clinical observation that 
these patients are signifi  cantly less likely to reject a liver trans-
plant than patients with other chronic liver diseases (  41, 42  ). 
It might also be expected to result in an impaired ability of 
CHB patients to control concurrent intrahepatic infections, 
particularly with other persistent noncytopathic viruses that 
are highly dependent on long-term T cell expansion and sur-
vival for their control. We suggest that the HBV-specifi  c 
response, already depleted by other mechanisms such as PD-
1  –  induced anergy (  26  ) and Bim-mediated apoptosis (  39  ), be-
comes more vulnerable to this additional global mechanism 
of intrahepatic T cell impairment than other more robust an-
tiviral responses. 
  We observed that global CD8 T cells capable of IFN-     
and TNF-     release are maintained in CHB patients with 
high viral load and liver infl  ammation. Although these two 
cytokines have the potential for noncytopathic inhibition of 
HBV replication (  43  ), they may also potentiate hepatocyte 
damage (  5  ). IFN-     is a proinfl  ammatory cytokine that in-
duces chronic hepatitis when constitutively expressed in the 
liver of transgenic mice (  44  ) and may also increase suscepti-
bility to TNF-mediated liver damage (  45  ). TNF-     has been 
demonstrated to mediate potent hepatocyte destruction, par-
ticularly when expressed in a cell-bound form (  46  ). This ef-
fect could be heightened in the HBV-infected liver, through 
the capacity of the HBx protein of HBV to sensitize hepa-
tocytes to TNF-mediated apoptosis (  47  ). IFN-     has been 
shown to stimulate the release of chemokines such as CXCL9 
and CXCL10 from hepatocytes, driving chemotaxis of the 
nonantigen-specifi  c hepatic infi  ltrate both in the transgenic 
mouse model of HBV (  48  ) and in human HCV infection 
(  49  ). Similarly, lung pathology resulting from the failure of 
CD8 control of infl  uenza and the subsequent infi  ltration of 
IU/liter;   Fig. 8 a  ).   These reductions in arginine concentra-
tion, although subtle, were in the dose range that we had 
shown to impair expansion of the HBV-specifi  c response in 
vitro (  Fig. 7 g  ). We would expect a more striking local de-
pletion of arginine within the liver, but this is diffi   cult to 
quantitate ex vivo because of activation of arginase during the 
homogenization of liver tissue required for arginine measure-
ment. Despite this caveat, we did fi  nd signifi  cantly lower lev-
els of arginine in the liver homogenates from CHB patients 
than those from patients with other types of liver disease (P   <   
0.05; unpublished data). 
  The conditionally essential amino acid   l  -arginine is pre-
dominantly depleted by arginase I, which breaks it down into 
its constituents, urea and ornithine (  20  ). Hepatocytes have the 
potential to be a potent source of arginase I (  34  ), as do mye-
loid suppressor cells (  20  ) and macrophages exposed to Th2 
cytokines such as IL-10 (  35  ). We investigated whether HBV-
related liver infl  ammation resulted in an up-regulation of 
arginase activity to account for our fi  ndings of arginine de-
pletion-dependent T cell defects in these patients. 
  Arginase activity was measured by its capacity to produce 
urea from an excess of arginine substrate (and standardized against 
the quantity of total protein extracted in the case of liver sam-
ples). Ex vivo serum arginase levels showed a nonsignifi  cant 
trend to be higher in CHB patients with active liver infl  am-
mation, but showed considerable variability within patient 
groups and controls (unpublished data). To remove the prob-
lem of interpatient variability, we therefore compared changes 
in arginase activity within two individuals with eAg-negative 
CHB who we were able to sample repeatedly over periods of 
rapid disease fl  uctuation (spontaneous hepatic fl  ares). Arginase 
activity in their serum showed large fl  uctuations upon longi-
tudinal assessment, with peaks correlating with fl  ares of dis-
ease activity as measured by HBV DNA and ALT levels (  Fig. 
8 b  ). Elevated arginase levels in the serum have been shown 
to refl  ect increased release from the relevant tissue source: the 
placenta in pregnancy (  36  ) and the liver in orthoptic trans-
plantation (  34  ). We therefore compared levels of arginase ac-
tivity in extracts prepared from liver samples from patients 
with or without CHB (  Table II  ). Arginase I activity was sig-
nifi  cantly increased in liver extracts taken directly ex vivo from 
patients with CHB compared with those from patients with 
other types of liver pathology (  Fig. 8 c  ). 
    DISCUSSION   
  CHB is characterized by an intrahepatic infl  ux of nonantigen-
specifi  c lymphocytes that fail to suppress viral replication and 
may instead give rise to liver damage (  3, 5, 37  ). In this study, 
we demonstrated a functional bias of CD8 T cells in CHB, 
which could contribute to both the failure of viral control 
and the pathogenesis of the resultant liver infl  ammation. We 
found that the global CD8 population (including CD8 spe-
cifi  c for HBV and for other chronic viruses), both in the cir-
culation and the liver, were skewed toward IFN-    /TNF     
production and impaired in their ability to produce IL-2 and 
proliferate. By scrutinizing the global CD8 T cells in CHB, JEM VOL. 205, September 1, 2008 
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ity (unpublished data). Whether enhanced arginase activity in 
these patients is dependent on the degree or type of liver in-
fl  ammation and/or on HBV itself, and whether it is mediated 
by hepatocytes and/or infi  ltrating MDSCs or macrophages, 
remains to be determined. 
  We found a dependence on   l  -arginine for complete re-
covery of CD3     in T cells from HBV patients, consistent with 
it being a contributory factor. CD8 T cell proliferative capac-
ity was more strikingly dependent on arginine replenishment, 
compatible with the recent observation that arginine deple-
tion also causes G0-G1 phase growth arrest independently of 
CD3     (  33  ). CD8 T cells from CHB patients showed some 
reconstitution of CD3     once they were removed from the 
source of antigenic stimulation and infl  ammation, even in the 
absence of arginine. Other factors are therefore likely to play 
a role in the infl  amed liver environment, such as depletion of 
other essential nutrients, infl  ammatory or immunosuppres-
sive cytokines, and accumulation of reactive oxygen inter-
mediates and other toxic metabolites. In particular, depletion 
of tryptophan and accumulation of tryptophan catabolites 
has also been shown to inhibit T cell proliferation via CD3     
down-regulation (  21, 22  ). CD3     down-regulation and argi-
nine deprivation have been noted to be most marked at the 
site of pathology (in the case of tumors for example), but to 
also extend to aff  ect T cells in the periphery. In keeping with 
this, we found CD3     down-regulation and arginase induc-
tion to be most accentuated in the liver but also detectable in 
the periphery. It is possible that other persistent infections 
capable of triggering an analogous infl  ammatory milieu in the 
liver would similarly bias T cell signaling and function. Along 
these lines it is worth noting that HCV has been found to 
have a pervasive infl  uence on non  –  antigen-specifi  c CD8 
T cells (  59  ). 
  In summary, we demonstrate for the fi  rst time that CD8 
T cells from patients with CHB have impaired IL-2 and prolif-
erative capacity, regardless of their specifi  city. Such functional 
skewing could impair their survival and anti-viral potential, 
particularly for persistent noncytopathic viruses in the CD4-
depleted liver environment. Their capacity for IFN-    /TNF-     
production could contribute to the proinfl  ammatory milieu, 
thereby exacerbating mechanisms underlying their dysfunc-
tion. The functional bias is corrected upon removal from the 
pathogenic environment and reversal of underlying signaling 
defects. Our data suggest that chronic exposure to the micro-
environment of an infl  amed liver could impair T cell eff  ector 
functions critical to the control of this virus. A major limita-
tion to the success of therapeutic vaccination in the setting 
of persistent virus infection such as HBV is thought to be 
the impaired T cell proliferative capacity (  60  ). Approaches 
to remedy these T cell defects in patients with CHB could 
therefore form an important adjunct to future immunothera-
peutic strategies. 
    MATERIALS AND METHODS   
  Subjects.     58 patients with CHB, 3 patients who had resolved acute HBV 
infection, and 28 healthy donors participated in the study. Informed consent 
non  –  antigen-specifi  c lymphocytes can be prevented by block-
ing IFN-     (  50  ). A recent study has shown that TNF-     can 
also switch the liver from a site of immunoprivilege to one 
susceptible to immune destruction by the T cells it indirectly 
chemoattracts (  51  ). Thus, a propensity of bystander CD8 T 
cells in CHB to produce IFN-     and TNF-     could further 
drive the nonantigen-specifi  c lymphocytic infi  ltrate and propa-
gate liver infl  ammation. 
  Studies have shown that HBV-specifi  c CD8 T cells are 
present at extremely low frequencies in the circulation and 
liver of patients with chronic infection (  3, 38  ), even when over-
lapping peptides are used to screen for responses to the whole 
viral genome (  25, 26  ). The dysfunction we have observed, 
aff  ecting all CD8 T cells, must therefore involve a   ‘  bystander  ’   
eff  ect, and we have specifi  cally shown that these defects 
extend to CD8 of unrelated specifi  cities. Such a bystander 
defect, aff  ecting all CD8 T cells regardless of specifi  city, has 
been attributed to down-regulation of the     -chain compo-
nent of the CD3 signaling complex in several malignant, auto-
immune, and infectious diseases (for review see [  12  ]). These 
conditions are all characterized by chronic antigenic stimula-
tion in the setting of persistent or recurrent infl  ammation, 
as is CHB. A mouse model of chronic bacterial infection 
dissected the mechanism whereby this combination led to 
global T cell      down-regulation and dysfunction, and confi  rmed 
the requirement for IFN-     together with sustained antigenic 
exposure (  11, 52  ), both of which are found in the HBV-
infected liver. Because most of our CHB patients with high 
viral load also had liver infl  ammation, we could not distin-
guish whether HBV infection and/or the infl  ammatory milieu 
associated with chronic liver damage drove the signaling and 
functional defects we found. 
  High local levels of IFN-     are postulated to recruit mye-
loid-derived suppressor cells (MDSC), which mediate global 
down-regulation of CD3     in surrounding T cells, an eff  ect 
that typically then extends from the infi  ltrating cells to aff  ect 
circulating populations (  11, 12, 53  ). Whether there is an in-
trahepatic accumulation of MDSC in CHB needs to be in-
vestigated, but would be in keeping with the infi  ltration of 
the HBV transgenic mouse liver with many cell types, in-
cluding granulocytes in response to IFN-      –  induced chemo-
kines (  54, 55  ). One of the mechanisms through which 
MDSCs may exert their eff  ect is through the consumption of 
  l  -arginine (  56, 57  ); reduced levels of this conditionally es-
sential amino acid have been associated with CD3     down-
regulation and impaired proliferation ( 20, 32, 56 ). Hepatocytes 
are also known to be a potent potential source of arginase I, 
which catabolizes arginine, and reduced   l  -arginine levels 
have been found after orthoptic liver transplantation (  34  ). 
The capacity of macrophages to take up and catabolize argi-
nine has been shown to be regulated by Th2 cytokines such 
as IL-10 and enhanced by an LPS-rich environment such as 
the liver (  35  ). We have recently found an increase in IL-10 in 
patients with fl  ares of HBV infection (  58  ), and there is a close 
temporal correlation between induction of IL-10 and the in-
creases in arginase activity we noted with HBV disease activ-2122 CD8 SKEWING IN HBV INFECTION   | Das et al. 
  Detection of CD3     after culture in   l  -arginine free medium.     PBMCs 
were plated in a 96-well round bottomed plate and incubated at 37  °  C for 
6 d in either    l  -arginine  –  depleted medium (GRH Biosciences) or    l  -arginine  –
  free medium supplemented with   l  -arginine (at 0.2 g/liter; Sigma-Aldrich). 
CD3     expression in CD8 T cells was then measured using on day 6. 
  CFSE proliferation assay.     PBMCs were washed 3 times in PBS, resus-
pended at 5   ×   10  6   ml in PBS and incubated for 10 min at 37  °  C with 0.5   μ  M 
CFSE (Invitrogen). An equal volume of FBS was added to quench the reac-
tion, and cells were subsequently washed twice in medium and 10% FBS, 
and then cultured with anti-CD3 mAb and anti-CD28 mAb. Cells were har-
vested at day 6 and stained with anti-CD8  –  Cychrome (PE-Cy5). Cells were 
then washed and resuspended in PBS with 0.1% formaldehyde and 1% FBS 
and acquired on a FACSCalibur. To determine proliferation of HBV-spe-
cifi  c CD8 T cells, PBMCs were stained for CFSE, and then stimulated with 
HBV c18-27 peptide, and on day 7, HBV-specifi  c CD8 were detected by 
costaining with anti-CD8-Cychrome (PE-Cy5) and an HLA-A2/c18-27-
specifi  c tetramer (PE; provided by A. Turner and P. Klenerman, Oxford 
University, Oxford, England, UK). These latter experiments were done in 
  l  -arginine  –  free medium, with or without the addition of   l  -arginine at the 
range of concentrations indicated. 
  Transfection of lymphocytes with chimeric receptor.     PBMCs were 
transfected with a human CD33-specifi  c chimeric receptor with intracellular 
CD28 in series with CD3     using the AMAXA electroporation protocol as 
previously described (  30  ). In brief, 1  –  3   μ  g of plasmid DNA was added to 
5   ×   10  6   cells, and resuspended in 100   μ  l of nucleofactor solution for T cells. 
Cells were then immediately electroporated in the AMAXA device with pro-
gram U-13 (Amaxa Biosystems), and then transferred into RPMI complete 
medium supplemented with 10% FBS at 37  °  C. 
  Detection of IL-2 production by ELISA.     Transfected cells were rested 
overnight at 37  °  C, after which 2   ×   10  5   cells were seeded into appropriate 
wells in a 96-well fl  at bottomed plate precoated with either 5   μ  g/ml CD33 
antigen, 1   μ  g/ml anti-CD3, both anti-CD3 and CD33 antigen, or neither 
as a negative control. Soluble anti-CD28 was added to the appropriate wells 
(5   μ  g/ml). Cells were then left in the incubator at 37  °  C for 48 h, after which 
supernatants were harvested. Enzyme-linked immunosorbent assays were 
then conducted in duplicate using the supernatants collected, according to the 
manufacturer  ’  s instructions (R  &  D Systems). 
  Measurement of arginase activity and arginine levels in serum and 
liver tissue homogenates.     Liver tissue was suspended in a TRIS/HCL 
buff  er containing a protease inhibitor cocktail (Sigma-Aldrich) and PMSF, 
and manually macerated with a glass mortar and pestle. The suspension was 
then centrifuged, and the clear homogenate was collected leaving the pre-
cipitate behind. 20   μ  l liver homogenate or serum was then combined with 
20   μ  l MnCl  2   (10 mM), 150   μ  l Tris Buff  er (pH 7.4, 50 mM), and 100   μ  l of 
  l  -arginine (50 mM; Sigma-Aldrich) for 30 min at 37  °  C. Arginine hydrolysis 
was stopped with 0.5 ml Tungstic acid solution (150 mM) containing con-
centrated hydrochloric and sulphuric acid (100 mM each). Unwanted par-
ticulate matter was pelleted by centrifuging at 5,000 RPM for 10 min at 
4  °  C. 200   μ  l of clear solution was used for detection of urea on a COBAS 
INTEGRA 400 using a UREAL kit assay (Roche). To subtract background 
serum urea levels, each experiment was duplicated substituting the   l  -argi-
nine substrate with 100   μ  l water. 1 U of arginase activity is defi  ned as the 
amount of enzyme required to catalyze formation of 1   μ  M urea per minute. 
To avoid any bias in arginase activity attributable to baseline diff  erences in 
protein content of the liver sections, protein content for each sample was 
determined by the Biurret test. This allowed arginase activity to be standard-
ized against protein content, expressed as IU/liter serum or IU/mg protein. 
    l  -arginine levels were determined by electrospray mass spectrometry. 
Samples (50   μ  l) were deproteinized with acetonitrile, chromatographed 
(acetonitrile/water, 1:1, with 0.025% formic acid) on a Teicoplanin guard 
column 10 mm   ×   2.1 mm ID (Chirobiotic T; ASTEC Ltd.), and analyzed 
was obtained, and the study was approved by the respective local ethical 
committees for the three participating clinics (Camden Primary Care Ethics 
Review Board, Royal Free Hospital and Medical School Research Ethics 
Committee, and Cambridge Research Ethics Committee). There was no 
signifi  cant diff  erence in demographic variables (age/gender) between patient 
and control groups (Table I). 24 of the CHB patients were positive for 
HBeAg, and 19 of these also had raised ALT (  >  50 IU/liter) and high HBV 
DNA (  >  10  6   IU/ml) as quantifi  ed by an in-house PCR-based assay. All other 
patients were HBeAg negative, and positive for serum anti-HBe antibody. 
Two of the patients in this study who had spontaneous fl  ares of eAg-negative 
CHB were followed up longitudinally and sampled repeatedly over several 
time points. Patients on antiviral therapy were excluded from the study. All 
patients were negative for antibodies to hepatitis C virus, delta virus, HIV-1, 
and HIV-2. 
  In addition, liver samples were obtained from 16 CHB-infected pa-
tients and from 15 patients with nonviral liver disease undergoing diagnostic 
liver biopsies or from resected tissue. Liver tissue was suspended in RPMI 
1640 (Applied Biosciences) and macerated in a Petri dish. The cell suspen-
sion was then passed through a 70-  μ  m fi  lter, and intrahepatic lymphocytes 
were isolated. 
  Separation of PBMCs and detection of CD28 and intracellular 
CD3    .     PBMCs were isolated from fresh heparinized blood by Ficoll-
Hypaque density gradient centrifugation and resuspended in RPMI 1640 
and 10% heat-inactivated FBS (Invitrogen). PBMCs were then plated (2   ×   
10  5   cells/well) into a 96-well round bottomed plate and incubated at 4  °  C for 
20 min with saturating concentrations of anti-CD3 PerCP-Cy5.5 mAb (BD 
Biosciences), anti-CD8  –  APC mAb (BD Biosciences), and anti-CD28-FITC 
mAb. After an additional wash in PBS, cells were fi  xed and permeabilized 
according to the manufacturer  ’  s protocol with Cytoperm/Cytofi  x for 
30 min at 4  °  C, after which intracellular staining was performed using anti-
TCR    -PE mAb (Coulter Immunotech) or its corresponding isotype con-
trol, IgG1-PE mAb in PBS containing 0.1% saponin to permeabilize the 
cells. Washed cells, resuspended in a solution of PBS, 0.1% formaldehyde, 
and 10% FBS, were acquired on a FACSCalibur (BD Biosciences) using Cell 
Quest Software, and data fi  les were analyzed using FlowJo software (Tree 
Star, Inc.). 
  Detection of IFN-    /IL-2/TNF-     production.     PBMCs were incubated 
at 37  °  C for 16 h in the presence of either anti-CD3mAb and -CD28mAb 
(BD Biosciences; reagents that act via the TCR) or phorbol myristic acetate 
(PMA at 3 ng/ml) and ionomycin (100 ng/ml; TCR-bypassing reagents) or 
medium alone as a negative control. 10   μ  g/ml Brefeldin A (Sigma-Aldrich) 
was added 1 h into the incubation time. PBMCs were then washed in PBS, 
stained with anti-CD8  –  Cychrome (PE-Cy5) mAb, and permeabilized and 
fi  xed with Cytoperm/Cytofi  x as detailed above. After a further wash in PBS, 
cells were stained with anti-IFN-    -PE mAb (R  &  D Systems) and anti-IL-2-
FITC mAb (R  &  D Systems) together or anti-TNF-     PE mAb alone in PBS 
containing 0.1% saponin at 4  °  C for 30 min. After two additional washes, cells 
were fi  xed and acquired immediately on a FACSCalibur fl  ow cytometer 
using Cell Quest Software. 
  CD107 degranulation assay.     PBMCs were stimulated for 16 h at 37  °  C in 
the presence of anti-CD3 and -CD28 in addition to anti-CD107a FITC. 
Monensin was added 1 h into the incubation time. Cells were then surface 
stained with anti-CD8-Cychrome (PE-Cy5; BD biosciences) and acquired 
on the FACSCalibur Cytometer. 
  Stimulation with synthetic viral peptides.     The following peptides rep-
resenting HLA-A2  –  restricted viral epitopes were used: CMV pp65 (NLVP-
MVATV), EBV BMLF1 (GLCTLVAML), infl  uenza matrix 1 (GILGFVFTL), 
HBV C18-27 (FLPSDFFPSV), and HBV envelope pool (FLLTRILTI, 
WLSLLVPFV, LLVPFVQWFV, and GLSPTVWLSV). PBMCs were stim-
ulated with 10   μ  M peptide for 12 h and incubated at 37  °  C in the presence 
of Brefeldin A (which was added 1 h into the incubation). JEM VOL. 205, September 1, 2008 
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